Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
3 Jan, 2023 (Tuesday)



EC HEALTHCARE(2138)
Analysis:
For the six months ended 30 September 2022, EC Healthcare (02138) had revenue of HK$1,893.2 million, up 31.1% YoY, while sales volume increased by 18.3% to HK$1,812.4 million. Net profit margin is under pressure and decreased by 8.0 percentage point to 5.6% due to the Compulsory Closure of the beauty and wellness businesses in Hong Kong and Macau as well as business disruption in Mainland China from COVID-19. The net profit attributable to equity shareholders of the Company decreased by 50.0% to HK$80.0 million. EC Healthcare had a total of 154 service points comprising 134 in Hong Kong, 4 in Macau and 16 in Mainland China with the total aggregate g.f.a. increased by 24.1% YoY to approximately 557,000 sq. ft. Company continues to gain market share in the healthcare services industry through both organic expansion and M&A growth. Revenue from medical services segment rose by 47.5% YoY to HK$1,174.8 million, boosting its revenue contribution to 62.1%. While Hong Kong local consumption was boosted by gradually recovers from the Hong Kong Government`s pandemic policy stance towards "Normalisation" with lifting of quarantine measures for inbound travelers. In addition, it is going to confirm the reopening of Hong Kong and Mainland China`s borders would reinstate demand from Mainland tourists, which could weaken the adverse impact of the challenging operation environment.
Strategy:
Buy-in Price: $8.03, Target Price: $8.95, Cut Loss Price: $7.36



Chow Tai Fook Jewellery (1929.HK) - Resilient Business Performance in 1HFY2023, resume normalcy become a positive catalyst

Resilient Business Performance in 1HFY2023

Chow Tai Fook Jewellery (CTF) revenue grew 5.3% to HK$46,535mn in1HFY2023. Revenue growth was driven by the steady expansion of retail network and robust demand for gold jewellery and products in the Mainland. Gross profit increased 1.6% to HK$10,962mn. Adjusted gross profit margin declined to 22.4% from 23.5% in the same period last year, mainly attributable to a higher share of our wholesale business and gold jewellery and products. Core operating profit was down by 2.7% to 4,349mn due to the flourishing wholesale business and a higher contribution from gold jewellery and products. Profit attributable to shareholders decreased by 6.8% to HK$3,336mn, mainly due to a net foreign exchange loss 268.9mn (1HFY2022: net gain of 46.6mn) arising from the weakening of RMB. EPS was HK$0.33, with an interim dividend of HK$0.22 per share in 1HFY2023, representing a payout ratio of approximately 66.0% (1HFY2022: 61.4%).

MAINLAND CHINA MARKET

Revenue in the Mainland was up 6.2% to HK$40,927mn in 1HFY2023. On a constant exchange rate basis, revenue increased by 9.3% in the period. Same Store Sales (SSS) dropped by 7.8% YoY (SSSG turned positive in 2QFY2023, and RSV increased by 28.0% YoY). SSS of gold jewellery and products was down 3.3% YoY. ASP of the product category increased to about HK$5,500 during the period (1HFY2022: HK$5,200). SSS of gem-set, platinum and k-gold jewellery dropped 13.9% during the period. Gem-set jewellery ASP climbed to approximately HK$7,500 (1HFY2022: HK$7,200).

As at 30 September 2022, there are 6,547 POS in Mainland China (4,929 franchised CHOW TAI FOOK JEWELLERY POS). Wholesale (mainly represents sales to franchisees and provision of services to franchisees) share in revenue expanded 630 basis points to 55.0% in the period. During the period, CTF opened a net of 933 CHOW TAI FOOK JEWELLERY POS in the Mainland (with approximately 90% of the net openings were franchised POS). RSV of franchised POS in the Mainland grew robustly by 29.2% YoY, and the growth was faster than that of the self-operated POS. E-commerce channel in the Mainland delivered an encouraging RSV growth of 15.1%. Its share to the RSV in the Mainland was steady at about 5.0%. In terms of retail sales volume, its share was about 13.0%. Its ASP was approximately HK$1,800 during the period (1HFY2022:HK$1,900).

HONG KONG & MACAU OF CHINA AND OTHER MARKETS

Revenue in Hong Kong, Macau and other markets was down by 0.5% to HK$5,608mn. Share to the Group's revenue amounted to 12.1%. Although retail revenue was improving in Hong Kong, wholesale revenue decreased by 25.1% mainly due to the pandemic-control measures in Hainan Province, which constrained the sales from duty-free business. SSSG increased by 1.3% YoY, while SSS volume growth was down by 8.7%. SSS of gold jewellery and products was up 6.1% in 1HFY2023, outperforming other product categories. ASP of the product category enjoyed an upward trend and reached about HK$7,000. SSS of gem-set, platinum and k-gold jewellery dropped 6.9% in the period. Yet, on a quarterly basis, it rebounded to positive growth in the second quarter. ASP of gem-set jewellery also increased by about 18% to HK$16,400. 89 POS in Hong Kong & Macau of China, closed a net of 3 POS. 43 POS in Other markets, while opened a net of 2 POS.

Investment Thesis

Management expected that 3QFY2023 performance to continue subdued as it was in 1QFY2023, mainly due to the prolonged impact of COVID in mainland China, and guided a high single digit sales decline in mainland China during 2HFY2023. However, some new products would be launched in during peak periods of consumption in Q4, and expect to help stabilize the sales. Management guided SSS growth of low-single-digit to mid-single-digit in mainland China, and teens growth in Hong Kong & Macau in FY2024. As the company expected to focus on improving store efficiency and growth quality, the number of net store openings will slow down to 600 to 800, and it is expected that FY2024 sales growth will be low-to-mid-teens. In addition, the company targeted to increase the proportion of self-operated stores in next year (higher gross profit margin than franchised), and with the help of product upgrade (the launch of the new Wonderful Life Collection) and reduced discounts, it is expected that there would be continued improvement of the overall core operating profit margin. We expected that there would be signs of recovery month-over-month in mainland China SSS since restrictions were gradually relaxed. We maintain FY2023-FY2024 EPS to be HKD0.79 and HKD0.92 respectively (reported on September 5, 2022), but considering that the return to normalcy in the Mainland will be a relatively positive catalyst, we raise the PT to HKD17.22, implies a FY2023E P/E of 21.7x (one standard deviation above 2-yrs historical average). Our investment rating is upgraded from “Neutral” to “Accumulate”.

Risk factors

1) Resurgence of COVID in Mainland China bring prolonged impact; 2) Sharp fluctuations in FX and gold price; 3) Economic recovery momentum slower-than-expected, consumer confidence weak; and 4) higher-than-expected operating costs.

Financial

Click Here for PDF format...




Recommendation on 3-1-2023
RecommendationAccumulate
Price on Recommendation Date$ 15.800
Suggested purchase priceN/A
Target Price$ 17.220
Writer Info
Eric Li
(Research Analyst)
Tel: (+852 2277 6516)
Email:
erichyli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2023 Phillip Securities (HK) Ltd. All Rights Reserved.